Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $86,063.20 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 3,580 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.04, for a total transaction of $86,063.20. Following the sale, the insider owned 195,825 shares of the company’s stock, valued at $4,707,633. This trade represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 4.5%

Shares of KMTS stock opened at $26.40 on Friday. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 12 month low of $14.30 and a 12 month high of $30.00. The stock has a market cap of $1.55 billion, a P/E ratio of -10.91 and a beta of 0.58. The company has a 50 day simple moving average of $22.96 and a two-hundred day simple moving average of $22.57.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. On average, research analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after acquiring an additional 474 shares in the last quarter. Brown Brothers Harriman & Co. grew its position in shares of Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares in the last quarter. Rhumbline Advisers raised its stake in Kestra Medical Technologies by 7.3% during the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock valued at $307,000 after purchasing an additional 874 shares during the period. Farther Finance Advisors LLC purchased a new position in Kestra Medical Technologies in the 4th quarter worth approximately $31,000. Finally, Police & Firemen s Retirement System of New Jersey lifted its holdings in Kestra Medical Technologies by 34.6% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after purchasing an additional 1,392 shares in the last quarter.

Wall Street Analysts Forecast Growth

KMTS has been the subject of several recent research reports. Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating for the company. BTIG Research raised their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research note on Wednesday, July 15th. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Finally, Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Kestra Medical Technologies currently has an average rating of “Hold” and a consensus target price of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.